Elicio Therapeutics (ELTX) Operating Expenses (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Operating Expenses for 7 consecutive years, with $10.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 3.35% year-over-year to $10.4 million; the trailing twelve-month figure through Jun 2026 stood at $37.9 million (down 15.07% YoY), and the FY2025 full-year result was $37.7 million, down 16.17% from the prior year.
• Operating Expenses eased to $10.4 million in Q2 2026 per ELTX's latest filing, from $10.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $16.1 million in Q1 2022 and bottomed at $5.8 million in Q3 2022.
• Historically, Operating Expenses has averaged $9.6 million across 5 years, with a median of $10.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses tumbled 66.82% in 2022, then jumped 86.67% in 2023.
• Over 5 years, Operating Expenses stood at $6.0 million in 2022, then soared by 57.56% to $9.4 million in 2023, then surged by 43.48% to $13.5 million in 2024, then tumbled by 34.39% to $8.8 million in 2025, then advanced by 17.95% to $10.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $10.4 million, $10.6 million, and $8.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.